BD (NYSE:BDX) announced today that it plans to transform the patient experience through a “One-Stick Hospital Stay” blood collection solution.
Franklin Lakes, N.J.–based BD said in a news release that its recent acquisition of Velano Vascular and its needle-free technology for high-quality blood draws from existing peripheral intravenous catheter (PIVC) lines offers a way to eliminate multiple needlesticks for blood sample collection.
Velano’s FDA-cleared PIVO device paves the way for the “One-Stick Hospital Stay” blood collection and vascular access initiative, providing certain low-acuity patients a chance to have just one “stick” across their entire stay in the hospital.
“As a global leader in vascular access solutions and blood collection, BD has been on the forefront of innovations that improve the patient experience and reduce additional needle sticks,” BD president of medication delivery solutions Rick Byrd said in the release. “Now, with the addition of Velano and its groundbreaking technologies, we can envision a world where a ‘One-Stick Hospital Stay’ could be a reality for many by making the numerous inpatient blood draws better for everyone.”
Terms of the acquisition of San Francisco–based Velano Vascular — named the fastest-growing medical device company in 2020 by Deloitte — were not disclosed. BD said the purchase aligns with its growth strategy for entering new categories that address unmet needs and “deliver higher impact to patients and health systems.”
“Since inception, we have long championed a more compassionate vision for quality vascular care for every patient in every hospital anywhere in the world,” Velano co-founder Eric M. Stone said. “By joining forces with BD, we can collectively accelerate the impact of our work to more rapidly make this shared vision of a ‘One-Stick Hospital Stay’ a reality.”